Company Encyclopedia
View More
name
Incannex Healthcare
IXHL.US
Incannex Healthcare Inc., a clinical-stage biopharmaceutical company, engages in the research and development of psychedelic medicines and therapies for patients with chronic diseases in Australia. The company develops IHL-42X, an oral fixed dose combination of dronabinol and acetazolamide that is in Phase 2/3 clinical trial for the treatment of obstructive sleep apnea; and PSX-001, an oral synthetic psilocybin treatment in Phase 2b clinical development for patients with generalized anxiety disorder. It is also developing IHL-675A, an oral fixed dose combination drug containing synthetic cannabidiol and hydroxychloroquine sulphate to treat rheumatoid arthritis, as well as lung inflammation, acute respiratory disease, chronic obstructive pulmonary disease, asthma, bronchitis, inflammatory bowel disease, colitis, and Crohn’s disease. Incannex Healthcare Inc.
4.513 T
IXHL.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
D
PharmaceuticalsIndustry
Industry Ranking144/183
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-114.52%E
    • Profit Margin-398933.33%E
    • Gross Margin0.00%E
  • Growth ScoreD
    • Revenue YoY-86.05%E
    • Net Profit YoY-106.76%E
    • Total Assets YoY390.53%A
    • Net Assets YoY1067.67%A
  • Cash ScoreD
    • Cash Flow Margin-0.03%D
    • OCF YoY-86.05%E
  • Operating ScoreE
    • Turnover0E
  • Debt ScoreA
    • Gearing Ratio2.17%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    FDA Grants Fast Track Designation to Incannex Healthcare for IHL-42X in Obstructive Sleep Apnea

    Incannex Healthcare Inc. has received Fast Track designation from the FDA for its product candidate IHL-42X, aimed at treating obstructive sleep apnea. This designation, based on positive clinical trial results, allows for more frequent FDA interactions and potential accelerated approval processes.

    Reuters·
    US
    IXHL
    -3.43%
    Reuters·
    US
    IXHL
    -3.43%

    Incannex Healthcare (NASDAQ:IXHL) Trading Up 1.1% - Still a Buy?

    Incannex Healthcare (NASDAQ:IXHL) shares rose 1.1% on Friday, trading at $0.3610. Despite the increase, Weiss Ratings maintains a "sell" rating, and the average analyst rating is "sell." The company reported better-than-expected quarterly earnings, but revenue fell short of estimates. Institutional investors have adjusted their stakes, with some increasing holdings. Incannex focuses on developing cannabinoid and psychedelic pharmaceuticals. Analysts suggest other stocks may be better investments.

    Market Beat·
    US
    IXHL
    -3.43%
    Market Beat·
    US
    IXHL
    -3.43%

    Incannex Healthcare reports Phase 2 data showing IHL-42X reduces AHI in obstructive sleep apnoea

    Incannex Healthcare reported a net loss of $6.4 million and operating expenses of $6.8 million, with $73.3 million in cash, ensuring a financial runway for at least twelve months. The company made significant progress in its clinical programs, notably with IHL-42X, which reduced the Apnoea-Hypopnoea Index by up to 83% in Phase 2 trials for obstructive sleep apnoea. Preparations for FDA interactions and further studies are underway.

    Reuters·
    US
    IXHL
    -3.43%
    Reuters·
    US
    IXHL
    -3.43%

    Incannex Healthcare Reports Increased Cash Reserves Amid Losses

    Incannex Healthcare Limited reported a Q1 comprehensive loss of $6.2 million, up from $5.1 million last year. Despite the loss, cash reserves increased to $73.3 million from $15.0 million, mainly due to share issuance proceeds. Operating expenses were $6.8 million, with R&D costs at $1.1 million and administrative expenses at $5.7 million. The company did not generate revenue this quarter. The management expects current cash reserves to support operations for the next twelve months as they focus on cannabinoid and psychedelic therapies.

    Tip Ranks·
    US
    IXHL
    -3.43%
    Tip Ranks·
    US
    IXHL
    -3.43%

    Incannex Healthcare | 10-Q: FY2026 Q1 Revenue: USD 0

    LB filings·
    US
    IXHL
    -3.43%
    LB filings·
    US
    IXHL
    -3.43%
    © 2025 Longbridge｜Disclaimer